Early onset pancreatic cancer: A controlled trial

Annals of Gastroenterology

Volumn 24, Issue 3, 2011, Pages 206-212

  Tingstedt, Bobby ^a   Weitkämper, Carl ^a   Andersson, Roland ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Early onset; Matched controls; Outcome; Pancreatic cancer

Indexed keywords

FLUOROURACIL; GEMCITABINE;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METASTASIS; ONSET AGE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS SURGERY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION;

EID: 79961236927     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Jemal A, Clegg L, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. CA Cancer J Clin 2004;101:3-27.
3. Loos M, Kleeff J, Friess H, Büchler M. Surgical treatment of pancreatic cancer. Ann N Y Acad Sci 2008;1138:169-180.
4. Andersson B, Aho U, Pendse M, Nilsson J, Tingstedt B, AnderssonR. Gemcitabine treatment in pancreatic cancer-prognostic factors and outcome. Ann Gastroenterol 2007;20:130-137.
5. Socialstyrelsen. The National Board of Health and Welfare;Statistical databases of cancer. http://www.socialstyrelsen.se/Statistik/statistikdatabas/index.htm 2009; June.
6. Raimondi S, Maisonneuve P, Löhr M, Lowenfels A. Early onsetpancreatic cancer: evidence of a major role for smoking and genetic factors. Cancer Epidemiol Biomarkers Prev 2007;16:1894-1897.
7. Duffy A, Capanu M, Allen P, et al. Pancreatic adenocarcinomain a young patient population - 12-year experience at Memorial Sloan Kettering Cancer Center. J Surg Oncol 2009;100:8-12.
8. Gawron A, Gapstur S, Fought A, Talamonti M, Skinner H. Sociodemographic and tumor characteristics associated with pancreatic cancer surgery in the United States. J Surg Oncol 2008;97:578-582.
9. Ferrone C, Brennan M, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008;12:701-706.
10. Baxter N, Whitson B, Tuttle T. Trends in the treatment andoutcome of pancreatic cancer in the United States. Ann Surg Oncol 2007;14:1320-1326.
11. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature2010;467:114-117.
12. Brand R, Greer R, Zolotarevsky E, et al. Pancreatic cancerpatients who smoke and drink are diagnosed at younger ages.Clin Gastroenterol Hepatol 2009;9:1007-1012.
13. Rulyak S, Lowenfels A, Maisonneuve P, Brentnall T. Risk factorsfor the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003;124:1292-1299.
14. James T, Sheldon D, Rajput A, et al. Risk factors associated withearlier age of onset in familial pancreatic carcinoma. Cancer 2004;101:2722-2726.
15. Efthimiou E, Crnogorac-Jurcevic T, Lemoine N, Brentnall T. Inherited predisposition to pancreatic cancer. Gut 2001;48:143-147.
16. Zhang J, Dhakal I, Yan H, Phillips M, Kesteloot H. Trends inpancreatic cancer incidence in nine SEER Cancer Registries, 1973-2002. Ann Oncol 2007;18:1268-1279.
17. Nöthlings U, Murphy SP, Hankin JH, Henderson BE, Kolonel LN. Meat and fat intake as risk factors for pancreatic cancer: themultiethnic cohort study. J Natl Cancer Inst 2005;97:1458-1465.
18. BerringtondeGonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003;89:519-523.
19. Li D, Morris J, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA2009;301:2553-2562.
20. Folhälsoinstitutet. Swedish National Institute of Public Health. http://www.fhi.se/sv/Statistik-uppfoljning/ 2010; April.
21. Hassan MM, Bondy ML, Wollf RA, et al. Risk factors for pancreaticcancer; Case-control study. Am J Gastroenterol 2007;102:2696-2707.
22. Goldstein A, Fraser M, Struewing J, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333:970-974.
23. Boardman L, Thibodeau S, Schaid D, et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann InternMed 1998;128:896-899.
24. Al-Sukhni W, Rothenmund H, Borgida A, et al. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. Hum Genet2008;124:271-278.
25. Brentnall T. Cancer surveillance of patients from familial pancreatic cancer kindreds. Med Clin North Am 2000;84:707-718.
26. Greer JB, Whitcomb DC. Role of BRCA 1 and BRCA 2 mutations in pancreatic cancer. Gut 2007;56:601-605.
27. Lüttges J, Stigge C, Pacena M, Klöppel G. Rare ductaladenocarcinoma of the pancreas in patients younger than age 40 years. Cancer 2004;100:173-182.
28. Bergmann F, Aulmann S, Wente M, et al. Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J ClinPathol 2006;59:580-584.
29. Hruban R, vanMansfeld A, Offerhaus G, et al. K-ras oncogeneactivation in adenocarcinoma of the human pancreas. A study of 82carcinomas using a combination of mutant-enriched polymerasechain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 1993;143:545-554.
30. Lüttges J, Diederichs A, Menke M, Vogel I, Kremer B, KlöppelG. Ductal lesions in patients with chronic pancreatitis show K-ras mutations in a frequency similar to that in the normal pancreas and lack nuclear immunoreactivity for p53. Cancer 2000;88:2495-2504.
31. Lindforss U, Papadogiannakis N, Zetterquist H, Lindberg G,Olivecrona H. Distribution of genetic variants in preneoplastic areas of colorectal tumours. Eur J Surg Oncol 2003;29:491-496.
32. Dive C, Smith R, Garner E, et al. Considerations for the use ofplasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer 2010;102:577-582.
33. Fujisawa T, Joshi B, Nakajima A, Puri R. A novel role ofinterleukin-13 receptor alpha2 in pancreatic cancer invasion and metastasis. Cancer Res 2009;69:8678-8685.
34. Mauro L, Grossoni V, Urtreger A, et al. PKC Delta (PKCdelta)promotes tumoral progression of human ductal pancreatic cancer. Pancreas 2010;39:31-41.
35. Melisi D, Niu J, Chang Z, et al. Secreted interleukin-1alphainduces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-kappaB. Mol Cancer Res 2009;7:624-633.